Furthermore, IVIS imaging conducted on days 3, 6, and 9 post-administration confirmed weaker luminescent signals in tumors treated with anti-PD-L1 antibody-modified LNPs, indicating superior tumor growth inhibition relative to other formulations (Figure 4A,B). The gene discussed is CD274; the disease is neoplasm.